- Home
- GSK
as 12-20-2024 4:00pm EST
In the pharmaceutical industry, GSK ranks as one of the largest firms by total sales. The company wields its might across several therapeutic classes, including respiratory, cancer, antiviral, and vaccines. GSK uses joint ventures to gain additional scale in certain markets like HIV.
| Founded: | 1715 | Country: | United Kingdom |
| Employees: | N/A | City: | N/A |
| Market Cap: | 69.7B | IPO Year: | N/A |
| Target Price: | $45.50 | AVG Volume (30 days): | 4.3M |
| Analyst Decision: | Hold | Number of Analysts: | 5 |
| Dividend Yield: | Dividend Payout Frequency: | Quarterly | |
| EPS: | 0.81 | EPS Growth: | -58.92 |
| 52 Week Low/High: | $32.83 - $45.93 | Next Earning Date: | 02-05-2025 |
| Revenue: | $41,966,224,352 | Revenue Growth: | 5.59% |
| Revenue Growth (this year): | 6.5% | Revenue Growth (next year): | 4.54% |
Latest GSK plc (Each representing two) News
GSK Breaking Stock News: Dive into GSK Ticker-Specific Updates for Smart Investing
TipRanks
5 days ago
GSK announces CHMP of the EMA recommended expanding approval of Jemperli
TipRanks
5 days ago
GSK announces FDA granted BTD for Jemperli
Pharmaceutical Technology
5 days ago
GSK’s lung cancer therapy gains EMA PRIME designation
Benzinga
11 days ago
GSK's Blood Cancer Drug Shows Improved Survival Compared To Johnson & Johnson's Darzalex
Business Wire
12 days ago
Belantamab Mafodotin shows significant overall survival benefit, reducing the risk of death by 42% in multiple myeloma at or after first relapse
Simply Wall St.
19 days ago
GSK (LON:GSK) investors are sitting on a loss of 3.4% if they invested five years ago
Morningstar Research
20 days ago
Analyst Report: GSK plc
Pharmaceutical Technology
a month ago
GSK gains approval in Japan for extended indication of RSV vaccine
Compare GSK vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "GSK GSK plc (Each representing two) - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.